Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
To start, Compass is a biotech stock. The company develops treatments for disease, specifically, it develops antibody therapeutics for cancer.
Due to the nature of its business, Compass, and other biotech stocks, can be difficult to judge from an investment perspective. That’s why I believe biotech ETFs make sense for many retail investors.
By investing in a biotech ETF, investors gain exposure to the dynamic companies reaching for the next breakthrough treatments for a whole range of ailments. Yet, investors are not over-exposed to any one particular company, whose stock price might plummet due to a rejection from the Food and Drug Administration (FDA) or disappointing results from a clinical trial.
Should you buy stock in Compass Therapeutics right now?
Before you buy stock in Compass Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Compass Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $519,015!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,086,211!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 2, 2026.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing was originally published by The Motley Fool
Content Original Link:
" target="_blank">
